Bio-Gene Technology (ASX:BGT) Total Receivables: A$0.03 Mil (As of Dec. 2025)


What is Bio-Gene Technology Total Receivables?

Bio-Gene Technology ASX:BGT Total Receivables is A$0.03 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's Total Receivables for the quarter that ended in Dec. 2025 was A$0.03 Mil.

Bio-Gene Technology Total Receivables Related Terms

Bio-Gene Technology Total Receivables Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Total Receivables Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial 0.52 0.44 0.45 0.52 0.47

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.52 0.10 0.47 0.03

Bio-Gene Technology Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$0.03 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Total Receivables of A$0.03 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Total Receivables too high?
Bio-Gene Technology's current Total Receivables is A$0.03 Mil.
How does Bio-Gene Technology's Total Receivables compare to VRTX and REGN?
Bio-Gene Technology's Total Receivables of A$0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Total Receivables is A$0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Total Receivables of A$0.03 Mil. The current Total Receivables is A$0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Total Receivables is A$0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.